

Overexpression of the Response Regulator *evgA* of the Two-Component Signal Transduction System Modulates Multidrug Resistance Conferred by Multidrug Resistance Transporters

KUNIHICO NISHINO AND AKIHITO YAMAGUCHI*

Department of Cell Membrane Biology, Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka 567-0047, Faculty of Pharmaceutical Science, Osaka University, Suita, Osaka 565-0871, and CREST, Japan Science and Technology Corporation, Osaka 567-0047, Japan

Received 14 August 2000/Accepted 16 November 2000

Overexpression of *evgA*, a response regulator of a two-component system, increased multidrug efflux in *Escherichia coli*. Since overexpression of the *emrKY* operon, which is controlled by *evgAS*, could account only for deoxycholate resistance, the *evgAS* locus apparently controls expression of at least one other multidrug efflux operon.

A currently favored mechanism underlying antibiotic resistance involves the extrusion of compounds by an efflux pump or carrier. The most intriguing drug extrusion mechanisms are those that involve a wide variety of structurally unrelated compounds as substrates for multidrug resistance (MDR) transporters. MDR transporters are found in a variety of bacterial species (4, 9, 12, 15). Many genes coding for MDR transporters have been mapped on *Escherichia coli* chromosomal DNA (16), but the transport capabilities of most of them have not been established. Recently we cloned all of them and investigated their drug resistance phenotypes (K. Nishino and A. Yamaguchi, unpublished data). During the course of that study, we found that the DNA locus including a putative transporter *emrKY* gene system (21) and two-component signal transduction *evgA* and *-S* genes (22) conferred multidrug resistance of *E. coli*. The *emrK* and *-Y* genes exhibit sequence similarity to the *emrA* and *-B* genes encoding a multidrug

exporter of *E. coli* (10), although the transport capabilities of *EmrK* and *Y* have not been elucidated. *EvgA* exhibits sequence similarity to the *BvgA* gene regulator, which controls the expression of adhesins, toxins, and other virulence factors in *Bordetella pertussis* (1, 18). Kato et al. reported that *evgAS* regulates the expression of *emrKY* (7).

To investigate the transport capabilities of *EmrK* and *-Y*, we amplified *emrK* and *-Y* genes with peripheral *evgA* and *-S* genes from the chromosomal DNA of *E. coli* W3104 by PCR using primers containing restriction enzyme *SphI* and *BamHI* sites, respectively. The DNA fragment was ligated into the *SphI* and *BamHI* sites of pUC118 to produce pUCSAKY. *E. coli* KAM3 (11), a derivative of K-12 that lacks multidrug transporter genes *acrA* and *-B*, was used for drug susceptibility testing. Resistance to various compounds was tested by plating diluted samples of overnight cultures on YT (17) agar containing various concentrations of compounds. *E. coli* KAM3 showed hy-

TABLE 1. Drug resistance of *E. coli* KAM3 cells harboring plasmids carrying *evgSA* and/or *emrKY*

| Drug | KAM3 (host) | MIC ($\mu\text{g/ml}$) for: | | | | | |
|----------------|-------------|-------------------------------|--------|-------|-------|---------|---------|
| | | KAM3 harboring: | | | | | |
| | | pUCSAKY | pUCAKY | pUCKY | pUCY | pUCAK | pUCA |
| Doxorubicin | 3.13 | 200 | 200 | 3.13 | 3.13 | 200 | 200 |
| Novobiocin | 0.78 | 1.56 | 1.56 | 0.78 | 0.78 | 1.56 | 1.56 |
| Erythromycin | 3.13 | 12.5 | 12.5 | 3.13 | 3.13 | 12.5 | 12.5 |
| Phosphomycin | 1.56 | 3.13 | 3.13 | 1.56 | 1.56 | 3.13 | 3.13 |
| Crystal violet | 1.56 | 6.25 | 6.25 | 1.56 | 1.56 | 6.25 | 12.5 |
| Rhodamine 6G | 6.25 | 50 | 50 | 6.25 | 6.25 | 50 | 50 |
| Ethidium | 12.5 | 25 | 25 | 12.5 | 12.5 | 25 | 25 |
| Acriflavine | 25 | 50 | 50 | 25 | 25 | 50 | 50 |
| Methylviologen | 100 | 200 | 200 | 100 | 100 | 200 | 200 |
| Benzalkonium | 3.13 | 25 | 25 | 3.13 | 3.13 | 25 | 25 |
| SDS | 100 | 200 | 200 | 100 | 100 | 300 | 300 |
| Deoxycholate | 1,250 | 5,000 | 10,000 | 1,250 | 1,250 | >40,000 | >40,000 |

* Corresponding author. Mailing address: Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki-shi, Osaka 567-0047, Japan. Phone: 81-6-6879-8545. Fax: 81-6-6879-8549. E-mail: akihito@sanken.osaka-u.ac.jp.


TABLE 2. Drug resistance of *E. coli* KAM3 cells harboring a plasmid carrying *emrKY* under control of the T5 promoter

| Drug | MIC ($\mu\text{g/ml}$) for: | | |
|----------------|-------------------------------|-------------------------|-------|
| | KAM3 | KAM3/pQE30 <i>emrKY</i> | |
| | | +IPTG | -IPTG |
| Doxorubicin | 3.13 | 3.13 | 3.13 |
| Erythromycin | 3.13 | 3.13 | 3.13 |
| Tetracycline | 0.78 | 0.78 | 0.78 |
| Crystal violet | 0.78 | 0.78 | 0.78 |
| Rhodamine 6G | 6.25 | 6.25 | 6.25 |
| Benzalkonium | 3.13 | 3.13 | 3.13 |
| SDS | 100 | 100 | 100 |
| Deoxycholate | 1,250 | 10,000 | 1,250 |

persensitivity to various drugs and toxic compounds (Table 1). *E. coli* KAM3 harboring pUCSAKY exhibited elevated resistance to several drugs and toxic compounds, including doxorubicin, novobiocin, erythromycin, phosphomycin, crystal violet, rhodamine 6G, ethidium, acriflavine, methylviologen, benzalkonium, and sodium dodecyl sulfate (SDS) (Table 1). To identify an MDR gene(s), several combinations of these four genes were individually subcloned. The resulting pUCAKY carries complete *evgA* and *emrKY* but not *evgS*. pUCKY carries *emrKY* but not *evgAS*. pUCY carries only complete *emrY*. pUCAK carries complete *evgA* and *emrK* but neither *evgS* nor *emrY*. pUCA carries only complete *evgA*, i.e., neither *evgS* nor *emrKY*. As a result, all plasmids that conferred multidrug resistance were found to contain *evgA*. pUCA, which contains only *evgA*, also exhibited multidrug resistance comparable to that of pUCSAKY. These observations indicated that *evgA* seems to be solely responsible for the multidrug resistance of the *evgSA* and *emrKY* loci. Thus, the results presented here indicate that the bacterial two-component signal transduction system may regulate multidrug resistance. Neither pUCKY nor pUCY conferred resistance to any compounds. Since *emrKY* might not be expressed from the native promoter, we cloned *emrKY* into the pQE30 expression vector to produce histidine-tagged proteins under the control of the T5 promoter (pQE30*emrKY*). Protein expression could be detected with antipolyhistidine antibodies (data not shown). pQE30*emrKY* conferred to *E. coli* KAM3 cells high-level resistance only to deoxycholate, not to the other compounds tested (Table 2). The deoxycholate resistance of *EmrKY* is in agreement with previous observations (7).

Since *emrKY* did not confer *evgA*-induced multidrug resistance, there was a possibility that *evgA* regulates other MDR system(s). When histidine-tagged *EvgA* expression was induced by isopropyl- β -D-thiogalactopyranoside in *E. coli* cells harboring pQE30*evgA*, a dense band corresponding to 23.5 kDa was observed on SDS-polyacrylamide gel electrophoresis (PAGE) of the membrane fraction (Fig. 1A, lane 4). This band was also detected on Western blotting with antipolyhistidine antibodies (Fig. 1B, lane 4). Thus, it is clear that this band represents *EvgA*-His₆. This protein was transferred to a supernatant on 5 M urea washing (data not shown), indicating that *EvgA* is a peripheral membrane protein. For the cytoplasmic fraction of *E. coli* KAM3/pQE30*evgA* cells (Fig. 1A and B, lanes 3), only a very faint band at 23.5 kDa was observed. On

(A) SDS-PAGE analysis



(B) Western blotting




FIG. 1. SDS-PAGE and Western blotting analysis of cells expressing *EvgA* and protein X. Membrane and cytoplasmic fractions of *E. coli* KAM3 and KAM3/pQE30*evgA* were prepared. The membrane (P) and cytoplasmic (S) fractions were then subjected to SDS-PAGE on 15% polyacrylamide gels. After electrophoresis, the gels were stained with Coomassie brilliant blue (A). Then proteins were electroblotted onto poly(vinylidene difluoride) membranes. Histidine-tagged *EvgA* was detected with antipolyhistidine antibodies (B).




FIG. 2. Amino acid sequences of protein X and the corresponding ORF on the *E. coli* chromosome. EvgA-induced protein X was eluted from an SDS polyacrylamide gel, and then its amino acid sequence was determined with a peptide sequencer. (A) The 10 sequenced amino acid residues are depicted as bold capital letters. The corresponding sequence encoded by the *yfdX* ORF is shown in the lower row. (B) Series of ORFs close to *evgAS* and *yfdX* in *E. coli* chromosomal DNA.

the other hand, a very dense band at 25 kDa was observed for the cytoplasmic fraction. Since this band was not detected on Western blotting with antipolyhistidine antibodies, it is clear that this protein is different from EvgA. This protein, named protein X, was induced by EvgA because *E. coli* KAM3 cells did not yield this protein band (Fig. 1A, lane 1). Protein X was eluted from the SDS-polyacrylamide gels, and its partial 10-amino-acid sequence was determined with a peptide sequencer (Fig. 2A). The resulting sequence, ADNAPVAAQQ, was completely consistent with the sequence of residues 22 to 31 of a putative protein encoded by the *yfdX* open reading frame (ORF). This ORF encodes a protein composed of 211 amino acids, but its function is not known. The *yfdX* ORF is close to the *evgA* and *-S* loci, and there are four ORFs (*yfdE*, *yfdV*, *yfdU*, and *yfdW*) between *evgS* and *yfdX* (Fig. 2B). The functions of these four ORFs are also not known. We cloned the *yfdX* ORF into the pQE70 expression vector. *E. coli* KAM3 cells harboring pQE70yfdX exhibited high level expression of 26-kDa histidine-tagged protein X, as observed on Coomassie brilliant blue staining (data not shown). However, protein X did not confer resistance to doxorubicin (data not shown). Thus, it seems that protein X represents an EvgSA-induced signal transduction pathway other than drug resistance. The ORFs, *yfdE*, *yfdV*, *yfdU*, and *yfdW*, between *evgS* and *yfdX* were also individually cloned into pUC118 under the control of the corresponding native promoters. None of the *E. coli* KAM3 cells harboring pUCyfdE, pUCyfdV, pUCyfdU, or pUCyfdW exhibited resistance to any compounds tested (data not shown), although the possibility that these genes were not expressed from their native promoters cannot be excluded.

Doxorubicin and rhodamine 6G were chosen as representative of drugs and toxic dyes to which *E. coli* KAM3 cells

became resistant with a plasmid carrying the *evgA* gene. These compounds can be detected by their fluorescence. To determine whether the *evgA*-induced multidrug resistance is due to multidrug efflux of these compounds from the cells, we measured the efflux of these compounds from cells preloaded with these compounds. Exponential cultures of *E. coli* KAM3, KAM3/pUCA, or KAM3/pQE30emrKY were harvested and washed twice with 100 mM potassium phosphate buffer (pH 7.5) containing 5 mM MgSO₄. For maximal accumulation of the fluorophore, the cells (optical density at 600 nm of 20 for doxorubicin or 1.0 for rhodamine 6G) were incubated with 1 μM rhodamine 6G or 11.5 μM doxorubicin and 40 μM carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) at 37°C for 1 h. The cells were then centrifuged, resuspended in the same medium containing 25 mM glucose to energize them, and subjected to fluorescence measurement. As shown in Fig. 3, rapid efflux of doxorubicin and rhodamine 6G from *E. coli* KAM3/pUCA cells was observed as an increase in the fluorescence. On the other hand, no significant efflux was observed from KAM3 and KAM3/emrKY cells. Plasmid pQE30emrKY did not affect the rate of efflux, indicating that EmrKY exported neither doxorubicin nor rhodamine 6G. The addition of the proton conductor CCCP inhibited the doxorubicin efflux from *E. coli* KAM3/pUCA cells (Fig. 3A), indicating that the active efflux is driven by a proton motive force. These observations clearly indicate that EvgA induces a doxorubicin and rhodamine 6G active efflux system(s) which is different from EmrKY.

Two-component systems are general signal transduction pathways in prokaryotic organisms responding to changes in environmental conditions (5, 14). They have also been found in some eukaryotes (8). A typical two-component system consists




FIG. 3. Active efflux of doxorubicin (A) and rhodamine 6G (B) from *E. coli* KAM3 cells harboring no plasmid, pUCA, or pQE30emrKY. Energy-starved cells of *E. coli* KAM3, KAM3/pUCA, and KAM3/pQE30emrKY cells were loaded with doxorubicin (A) or rhodamine 6G (B). The fluorescence of the compounds was continuously monitored with a Hitachi model F-2000 fluorescence spectrophotometer. Doxorubicin transport was measured with excitation at 478 nm and emission at 591 nm. Rhodamine 6G transport was measured with excitation at 529 nm and emission at 553 nm.

of two types of signal transducers, a sensory kinase and a response regulator (20). The sensory kinase monitors some environmental parameters and accordingly modulates the functions of the response regulator through its phosphorylation (6, 19). The response regulator mediates gene expression and/or cell behavior. Recently, it was found that a two-component system regulates bacterial drug resistance. VncRS in *Streptococcus pneumoniae* (13) and VanRS in enterococci (2) regulate vancomycin resistance. It was subsequently reported that another two-component system, ArIRS, in *Staphylococcus*

aureus regulates the expression of multidrug transporter NorA (3). In this study, we found that overexpression of the response regulator *evgA* of the two-component signal transduction system modulates multidrug resistance conferred by MDR transporters in *E. coli*. The findings in this study indicate that two-component system-controlled multidrug resistance via multidrug exporter(s) may be another general way for bacteria to acquire multidrug resistance.

REFERENCES

1. Arico, B., V. Scarlato, D. M. Monack, S. Falkow, and R. Rappuoli. 1991. Structural and genetic analysis of the *bvg* locus in *Bordetella* species. *Mol. Microbiol.* 5:2481–2491.
2. Arthur, M., C. Molinas, and P. Courvalin. 1992. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in *Enterococcus faecium* BM4147. *J. Bacteriol.* 174:2582–2591.
3. Fournier, B., R. Aras, and D. C. Hooper. 2000. Expression of the multidrug resistance transporter NorA from *Staphylococcus aureus* is modified by a two-component regulatory system. *J. Bacteriol.* 182:664–671.
4. George, A. M. 1996. Multidrug resistance in enteric and other gram-negative bacteria. *FEMS Microbiol. Lett.* 139:1–10.
5. Hock, J. A., and T. J. Silhavy (ed.). 1995. Two-component signal transduction. American Society for Microbiology, Washington, D.C.
6. Inouye, M. 1996. His-Asp phosphorylation: two components or more? *Cell* 85:13–14.
7. Kato, A., H. Ohnishi, K. Yamamoto, E. Furuta, H. Tanabe, and R. Utsumi. 2000. Transcription of *emrKY* is regulated by the *EvgA-EvgS* two-component system in *Escherichia coli* K-12. *Biosci. Biotechnol. Biochem.* 64:1203–1209.
8. Kennelly, P. J., and M. Potts. 1996. Fancy meeting you here! A fresh look at “prokaryotic” protein phosphorylation. *J. Bacteriol.* 178:4759–4764.
9. Lewis, K. 1994. Multidrug resistance pumps in bacteria: variations on a theme *Trends Biochem. Sci.* 19:119–123.
10. Lomovskaya, O., and K. Lewis. 1992. Emr, an *Escherichia coli* locus for multidrug resistance. *Proc. Natl. Acad. Sci. USA* 89:8938–8942.
11. Morita, Y., K. Kodama, S. Shiota, T. Mine, A. Kataoka, T. Mizushima, and T. Tsuchiya. 1998. NorM, a putative multidrug efflux protein, of *Vibrio parahaemolyticus* and its homolog in *Escherichia coli*. *Antimicrob. Agents Chemother.* 42:1778–1782.
12. Nikaïdo, H. 1996. Multidrug efflux pumps of gram-negative bacteria. *J. Bacteriol.* 178:5853–5859.
13. Novak, R., B. Henriques, E. Charpentier, S. Normark, and E. Tuomanen. 1999. Emergence of vancomycin tolerance in *Streptococcus pneumoniae*. *Nature* 399:590–593.
14. Parkinson, J. S. 1993. Signal transduction schemes of bacteria. *Cell* 73:857–871.
15. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. *Microbiol. Rev.* 60:575–608.
16. Paulsen, I. T., M. K. Sliwinski, and M. H. Saier, Jr. 1998. Microbial genome analyses: global comparisons of transport capabilities based on phylogenies, bioenergetics and substrate specificities. *J. Mol. Biol.* 277:573–592.
17. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
18. Stibitz, S., and M. S. Yang. 1991. Subcellular localization and immunological detection of proteins encoded by the *vir* locus of *Bordetella pertussis*. *J. Bacteriol.* 173:4288–4296.
19. Stock, J. B., A. J. Ninfa, and A. M. Stock. 1989. Protein phosphorylation and regulation of adaptive responses in bacteria. *Microbiol. Rev.* 53:450–490.
20. Stock, J. B., M. G. Surette, M. Levit, and A. M. Stock. 1995. Two-component signal transduction systems: structure-function relationships and mechanisms of catalysis, p. 25–51. In J. A. Hoch and T. J. Silhavy (ed.), *Two-component signal transduction*. American Society for Microbiology, Washington, D.C.
21. Tanabe, H., K. Yamasaki, M. Furue, K. Yamamoto, A. Kato, M. Yamamoto, S. Yoshioka, H. Tagami, H. Aiba, and R. Utsumi. 1997. Growth phase-dependent transcription of *emrKY*, a homolog of multidrug efflux *emrAB* genes of *Escherichia coli*, is induced by tetracycline. *J. Gen. Appl. Microbiol.* 43:257–263.
22. Utsumi, R., S. Katayama, M. Taniguchi, T. Horie, M. Ikeda, S. Igaki, H. Nakagawa, A. Miwa, H. Tanabe, and M. Noda. 1994. Newly identified genes involved in the signal transduction of *Escherichia coli* K-12. *Gene* 140:73–77.